Anti-IL31 antibodies for veterinary use
Provided are various embodiments relating to anti-IL31 antibodies having enhanced binding to canine IL31 and feline IL31. Such antibodies can be used in methods to treat IL31-induced conditions in companion animals, such as canines and felines. Antibodies with enhanced binding to canine IL31 and feline IL31 are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind canine and feline IL31 are also provided.
1 . An antibody that binds to canine IL31 or feline IL31, wherein the antibody comprises:
a) a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 11, a CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 14 or SEQ ID NO: 15; and
b) a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 20, a CDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 23 or SEQ ID NO: 24.
2 . The antibody of claim 1 , wherein the antibody comprises:
a) a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 11, a CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15; and
b) a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 20, a CDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 24.
3 . The antibody of claim 1 comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 6 or SEQ ID NO: 7.
4 . The antibody of claim 1 comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 9 or SEQ ID NO: 10.
5 . The antibody of claim 1 , wherein the antibody comprises:
a) a heavy chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 11, a CDR2 comprising the amino acid sequence of SEQ ID NO: 12, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15; and
b) a light chain comprising a CDR1 comprising the amino acid sequence of SEQ ID NO: 20, a CDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 24;
wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence with at least 95% identity to SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence with at least 95% identity to SEQ ID NO: 10.
6 . The antibody of claim 5 , wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence with at least 98% identity to SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence with at least 98% identity to SEQ ID NO: 10.
7 . The antibody of claim 5 , wherein the antibody comprises a heavy chain variable region comprising an amino acid sequence with at least 99% identity to SEQ ID NO: 7 and a light chain variable region comprising an amino acid sequence with at least 99% identity to SEQ ID NO: 10.
8 . The antibody of claim 5 , wherein the antibody comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 7 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 10.
9 . The antibody of claim 1 comprising a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, or SEQ ID NO: 90.
10 . The antibody of claim 1 comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 52, SEQ ID NO: 53, or SEQ ID NO: 54.
11 . A bispecific antibody comprising the antibody of claim 1 and an antibody that binds to an antigen selected from IL17, TNFα, CD20, CD19, CD25, IL4, IL13, IL23, IgE, CD11α, IL6R, α4-Intergrin, IL12, IL1β, and BlyS.
12 . A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.
13 . A method of treating a canine or feline having an IL31-induced condition, the method comprising administering to the canine or feline a therapeutically effective amount of the pharmaceutical composition of claim 12 , wherein the IL31-induced condition is selected from atopic dermatitis, allergic dermatitis, pruritus, asthma, psoriasis, scleroderma, and eczema.
14 . A method of reducing IL31 signaling function in a cell expressing an IL31 receptor, the method comprising exposing to the cell the pharmaceutical composition of claim 12 in the presence of the IL31.
15 . A method of treating a canine or feline having an IL31-induced condition, the method comprising administering to the canine or feline a therapeutically effective amount of the antibody of claim 1 , wherein the IL31-induced condition is selected from atopic dermatitis, allergic dermatitis, pruritus, asthma, psoriasis, scleroderma, and eczema.
16 . A method of reducing IL31 signaling function in a cell expressing an IL31 receptor, the method comprising exposing to the cell the antibody of claim 1 in the presence of the IL31.
17 . A method for detecting IL31 in a sample from a canine or feline comprising contacting the sample with the antibody of claim 1 under conditions permissive for binding of the antibody to IL31, and detecting a complex formed between the antibody and IL31 in the sample.
18 . An isolated nucleic acid encoding the antibody of claim 1 .
19 . A host cell comprising the nucleic acid of claim 18 .
20 . A method of producing the antibody encoded by the nucleic acid of claim 18 , comprising culturing a host cell transformed or transfected with the nucleic acid, and isolating the antibody.